Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results on March 12, 2
27 February 2009 - 11:00PM
PR Newswire (US)
BETHESDA, Md., Feb. 27 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that that it will host a
conference call and audio webcast on Thursday, March 12, 2009, at
9:00 am Eastern Time (2:00 pm Central European Time) to discuss its
financial results for the fourth quarter and the full year of 2008.
Micromet anticipates releasing its financial results at 7:00 am
Eastern Time (12:00 pm Central European Time) on Thursday, March
12, 2009. To participate in this conference call, dial 800-659-1966
(U.S.) or 617-614-2711 (international), passcode: 20334467. The
audio webcast can be accessed at http://www.micromet-inc.com/ in
the investor relations section of the website. A replay of the call
will be available from 12:00 pm Eastern Time on March 12, 2009
(5:00 pm Central European Time) through Thursday, March 19, 2009.
The replay number is 888-286-8010 (U.S.) or 617-801-6888
(international), passcode: 99301894. About Micromet, Inc. Micromet,
Inc. (http://www.micromet-inc.com/) is a biopharmaceutical company
with offices in Bethesda, MD and Munich, Germany. The Company is
focused on developing novel, proprietary antibodies for the
treatment of cancer, inflammation and autoimmune diseases. The
Company's novel antibody technology is based on its proprietary
BiTE(R) antibody platform, representing a new class of antibodies
that specifically activate T cells from the patient's own immune
system to eliminate cancer cells or other disease related cells.
Four of the Company's antibodies are currently in clinical trials,
with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia and a phase
1 clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, LLC, a subsidiary of AstraZeneca plc. Micromet's second
BiTE antibody in clinical development is MT110, which targets the
epithelial cell adhesion molecule (EpCAM). The Company owns all
rights to MT110, which is currently in a phase 1 clinical trial for
the treatment of patients with solid tumors. The Company's third
clinical stage antibody is adecatumumab, also known as MT201, a
traditional human monoclonal antibody that targets EpCAM-expressing
solid tumors. Micromet is developing adecatumumab in collaboration
with Merck Serono in a phase 1b clinical trial evaluating
adecatumumab in combination with docetaxel for the treatment of
patients with metastatic breast cancer. Micromet licensed a fourth
clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc.
MT293 is being developed in a phase 1 clinical trial for the
treatment of patients with cancer. The Company's preclinical
programs include MT203 being developed in collaboration with
Nycomed. MT203 is a traditional human antibody neutralizing the
activity of granulocyte/macrophage colony stimulating factor
(GM-CSF), which has potential applications in the treatment of
inflammatory and autoimmune diseases, such as rheumatoid arthritis,
psoriasis, or multiple sclerosis. Micromet has granted an exclusive
option to Bayer Schering Pharma AG to license a BiTE antibody
against an undisclosed solid tumor target. Additional BiTE
antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively,
are in different stages of preclinical development. Forward-Looking
Statements This release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. These forward-looking statements include statements
regarding the efficacy, safety and intended utilization of our
product candidates, the development of our BiTE antibody
technology, the conduct, timing and results of future clinical
trials, expectations of the future expansion of our product
pipeline and collaborations, and our plans regarding future
presentations of clinical data. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities
relating to our product candidates. These factors and others are
more fully discussed in Micromet's Annual Report on Form 10-K for
the fiscal year ended December 31, 2007, filed with the SEC on
March 14, 2008, as well as other filings by the company with the
SEC. Any forward-looking statements are made pursuant to Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, and, as such,
speak only as of the date made. Micromet, Inc. undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.
DATASOURCE: Micromet, Inc. CONTACT: US Media: Andrea tenBroek, or
Chris Stamm, +1-781-684-0770, ; or US Investors: Susan Noonan,
+1-212-966-3650, ; or European Media: Ludger Wess,
+49(40)8816-5964, ; or European Investors: Ines-Regina Buth,
+49(30)2363-2768, Web Site: http://www.micromet-inc.com/
Copyright